Investor Confidence - Ihealthfull

pharma

NATCO Pharma Semaglutide: Clear Approval Boosts Stock by 12%

Joseph Davis Oct 3, 2026 0

NATCO Pharma Semaglutide gains 12% after CDSCO approval in India. Discover the impact on the market and future prospects.

Read More

YOU MAY HAVE MISSED

pharma

NATCO Pharma Semaglutide: Clear Approval Boosts Stock by 12%

Joseph Davis Oct 3, 2026

drug price gap

pharma

Drug Price Gap: Why the 16% Cap is Wrong

Joseph Davis Sep 29, 2026

lower drug prices

pharma

Lower Drug Prices: Proven Ways to Reform Patent System

Joseph Davis Sep 26, 2026

Azerbaijan Oncology Approval

pharma

Azerbaijan Oncology Approval: Best Proven Updates for Beta Drugs

Joseph Davis Sep 22, 2026